FANG Vaccine Markedly Decreases Disease Recurrence in Phase II Ovarian Cancer Trial

SGO conference report

A 2:1 open-label phase II trial of the FANG vaccine achieved a marked delay in time to progression, in all 14 of 21 patients with stage III/IV ovarian cancer who participated. The other 7 patients did not receive the vaccine. The data were presented March 28 in Chicago, at the 2015 Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
- See more at: http://www.targetedonc.com/conference/sgo-2015/FANG-Vaccine-Markedly-Decreases-Disease-Recurrence-in-Phase-II-Ovarian-Cancer-Trial#sthash.WJglSoeW.dpuf